More than 25,000 participants were recruited to these studies.
A total of 295 new clinical research studies received approval to start recruitment in 2023-24, just over one-third of which were funded by industry partners, which includes companies paying for the new treatments or medical devices, clinical tests and our staff.
All new studies have to be approved and prioritised by a Local Research Oversight Group (LROG), which are made up of Trust clinical and administration staff who are interested in bringing research opportunities to OUH patients.
Around 82 percent of the new studies are part of the National Institute for Health and Care Research (NIHR) portfolio. Some 520 of these NIHR-supported studies reported recruitment in 2023-24, more than any other NHS Trust in England.
Over 370 clinical research delivery staff working across 38 teams support the delivery of these studies.
Most of the studies hosted by OUH are sponsored by external entities, with the largest being the University of Oxford, responsible for 25 percent of our active clinical trials.
We work closely with pharmaceutical companies, technology developers and other hospitals and universities within the UK and internationally.
The studies vary from the testing of new drugs and devices to observational studies.
The large number and wide variety of clinical research hosted by OUH has major benefits for our patients, as well as cementing the Trust’s reputation for being a centre for healthcare innovation.
The clinical advances developed in Oxford have established new diagnostics and treatments, changed clinical guidelines for many conditions and have led to multiple spin-out companies, boosting the local economy.
Read our latest Performance and Governance Report:
Research & Development Governance and Performance Report 2023-24 (pdf, 902 KB)
